Negative p53/Positive p21 Immunostaining Is a Predictor of Favorable Response to Chemotherapy in Patients with Locally Advanced Bladder Cancer

Fumitaka Koga,1, 2 Satoshi Kitahara, Kyoko Arai, Mikihiro Honda, Shuhei Sumi and Ken-ichiro Yoshida

Department of Urology, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga-gun, Tochigi 321-0207

The relationship between clinical response to DNA-damaging drugs and p53 and p21 status in patients with locally advanced transitional cell carcinoma (TCC) of the bladder was assessed. The response to intraarterial chemotherapy (IAC) comprising 100 mg/m² of cisplatin (CDDP) and 40 mg/m² of pirarubicin (THP) and the prognosis were assessed in 23 patients (the mean follow-up period was 19 months). The p53 gene status of tumors was analyzed at exons 5–8 using polymerase chain reaction-single strand conformation polymorphism analysis in 19 patients, and paraffin-embedded tumor sections were immunostained for p53 and p21 in 23 patients. The overall objective response rate (incidence of good responders) was 70%. The negative p53 group (n=17) showed a significantly higher objective response rate than the positive p53 group (n=6) (82% vs. 33%; P=0.045). The p53 gene status or p21 staining status was not significantly associated with responsiveness. When the p53 and p21 immunostaining results were combined, good responders were more accurately predicted than by p53 staining status alone; the negative p53/positive p21 group (n=12) showed an objective response rate of 92%, which was significantly higher than that of the positive p53 and/or negative p21 group (45%, n=11) (P=0.027). Cause-specific survival of the negative p53 group was significantly superior to that of the positive p53 group (P=0.015). Negative p53/positive p21 immunostaining is a possible predictor of favorable chemotherapeutic response in patients with TCC of the bladder.

Key words: p53 — p21 — Chemosensitivity — Transitional cell carcinoma — Bladder

Although radical cystectomy remains the standard treatment for muscle-invasive (≥T2) bladder cancer, a variety of adjuvant treatments have been tried to induce down-staging of the tumor, treat micrometastases, and ultimately improve long-term survival.1–4 Neoadjuvant chemotherapy including intraarterial chemotherapy (IAC), administered prior to surgery, reportedly lowers the stage of the tumor and consequently allows the bladder to be preserved by transurethral resection (TUR) or partial cystectomy in 25 to 50% of patients with invasive bladder cancer.1,3–5 However, this therapy is potentially harmful as well as unnecessary for patients whose tumor will not respond to the treatment. Accordingly, it is important to identify the characteristics associated with responses to the treatment.

The wild type (wt) p53, a tumor suppressor protein, results in several outcomes including growth arrest, cell death and DNA repair.6 The p21 protein, the product of a downstream target gene for wt p53 protein, also induces growth arrest, cell death and DNA repair through inhibiting cyclin-dependent kinases and proliferating cell nuclear antigen (PCNA).7–10 DNA-damaging drugs up-regulate wt p53 and p21; the latter could be induced even in cells bearing mutant type (mt) p53 gene through a p53-independent pathway.11–13 As expected, p53 and p21 status may affect chemosensitivity. Concerning the roles of p53 and p21 in drug sensitivity, mutually exclusive opinions have been put forward: (1) wt p53 and p21 increase sensitivity by favoring induction of apoptosis11–14 and (2) wt p53 and p21 decrease sensitivity by enhancing DNA repair.15,16

Herein, we investigated the relationship between p53 and p21 status in pretreatment biopsied tumor tissue and clinical response to IAC composed of two DNA-damaging drugs, cisplatin (CDDP) and pirarubicin (THP), in patients with locally advanced transitional cell carcinoma (TCC) of the bladder.

MATERIALS AND METHODS

Case materials Between May 1995 and May 1998, 23 patients (4 females and 19 males) diagnosed as locally invasive (T2–4,N0,M0) TCC of the bladder or T1b,N0,M0 disease with multiple large tumors considered incurable by TUR alone, received one or two courses of IAC at the Univer-
sity Hospital, Dokkyo University School of Medicine. Staging was based on the 1997 TNM system. The median age of patients was 67 years (range 42–87).

Specimens were biopsied transurethrally in each patient for histopathological diagnosis based on the guideline of the Japanese Urological Association. Residual tumor volume after biopsy was large enough to assess IAC response. The therapeutic effect of IAC on the tumor and p53 and p21 immunoreactivity in pretreatment tumor specimens were evaluated in 23 patients. In addition, the p53 gene status was investigated in 19 patients (Table I).

**IAC regimen** Using Seldinger’s technique, each balloon catheter (5F) was placed in the contralateral internal iliac artery and angiography was carried out to identify tumor vessels. Following balloon inflation, 100 mg/m² of CDDP and 40 mg/m² of THP were administered for 30 and 15 min, respectively, using infusion pumps. The dose for each side was determined according to the clinical tumor location and the degree of tumor stain on angiography. In the case of poor general status or renal function, the dose given was reduced.

**Response to IAC** Approximately 4 weeks after the last course of IAC, the therapeutic effect was assessed pathologically in 14 patients undergoing total or partial cystectomy, and only clinically in the other 9 patients. Pathological and clinical response criteria were as follows, based on the guideline of the Japanese Urological Association: Grade 2, presence of viable cells in less than 1/3 of tumor tissue. Grade 1-b, presence of viable cells in 1/3 or more but less than 2/3 of tumor tissue. Grade 1-a, presence of viable cells in 2/3 or more of tumor tissue. Grade 0, no morphological therapeutic change.

**Clinical response:** cCR—clinical complete response, disappearance of tumor based on clinical and cytopathological examination. cPR—clinical partial response, 50% or more reduction in the size of tumor masses according to two-dimensional measurement but cytopathological evidence of tumor. cNC—clinical no change, less than 50% of viable tumor cells.

| Case no. | Age/sex | Structure | Grade | Stage | p53 gene | p53 | p21 | No. IAC | Clinical response | Pathological response | Tx | Time to PD (m) | Outcome | Follow-up (m) |
|----------|---------|-----------|-------|-------|----------|-----|-----|--------|-----------------|---------------------|----|---------------|---------|---------------|
| 1        | 71/M    | N         | G3    | ≥pT1c | wt       | 0   | 0   | 1      | cCR             | grade 3             | TC | —             | NED     | 30            |
| 2        | 75/M    | P         | G1>2  | ≥pT1b | wt       | 0   | 2   | 1      | cPR             | grade 2             | TC | 20            | DOD     | 26            |
| 3        | 48/M    | P         | G2    | ≥pT1b | wt       | 0   | 2   | 2      | cPR             | grade 2             | TC | —             | NED     | 42            |
| 4        | 61/M    | P         | G1>2  | ≥pT1b | wt       | 0   | 0   | 1      | cNC             | grade 1b            | TC | —             | DOO     | 3             |
| 5        | 64/M    | P         | G2>1  | ≥pT1a | wt       | 0   | 0   | 1      | cNC             | grade 1b            | TC | 8             | DOD     | 12            |
| 6        | 79/M    | N         | G3    |        | wt       | 0   | 0   | 2      | cCR             | grade 3             | PC | —             | NED     | 39            |
| 7        | 76/M    | N         | G2    | ≥pT1a | wt       | 0   | 2   | 1      | cCR             | —                   | —  | 21            | AWD     | 23            |
| 8        | 71/F    | P         | G3    | ≥pT1a | wt       | 0   | 3   | 2      | cCR             | —                   | —  | 16            | AWD     | 19            |
| 9        | 77/F    | P         | G3    | ≥pT1a | wt       | 2   | 0   | 2      | cNC             | —                   | TUR| 6             | DOD     | 13            |
| 10       | 67/M    | N         | G2    | ≥pT1a | wt       | 0   | 3   | 1      | cPR             | —                   | TUR| 16            | AWD     | 19            |
| 11       | 63/M    | N         | G3    | ≥pT1a | wt       | 2   | 3   | 1      | cNC             | grade 0             | TC | —             | NED     | 20            |
| 12       | 87/M    | N         | G3    | ≥pT1a | wt       | 2   | 3   | 1      | cPR             | —                   | TUR| 7             | AWR     | 7             |
| 13       | 61/M    | N         | G3    | ≥pT1a | mt       | 2   | 2   | 2      | cPR             | grade 2             | TC | 3             | DOD     | 5             |
| 14       | 60/M    | N         | G2>3  | ≥pT1a | mt       | 3   | 2   | 2      | cNC             | grade 0             | TC | 9             | DOD     | 15            |
| 15       | 73/M    | N         | G3    | ≥pT1a | mt       | 3   | 0   | 1      | cNC             | grade 0             | TC | —             | DOO     | 3             |
| 16       | 76/M    | N         | G3    | ≥pT1a | mt       | 0   | 2   | 1      | cPR             | grade 2             | TC | —             | NED     | 26            |
| 17       | 50/F    | N         | G3    | ≥pT1a | mt       | 0   | 3   | 1      | cNC             | grade 0             | TC | 3             | AWD     | 14            |
| 18       | 83/F    | P         | G3    | ≥pT1a | mt       | 0   | 2   | 2      | cPR             | —                   | TUR| 11            | AWR     | 15            |
| 19       | 67/M    | P         | G2    | ≥pT1a | mt       | 0   | 2   | 1      | cPR             | —                   | TUR| —             | NED     | 14            |
| 20       | 63/M    | N         | G3    | ≥pT1a | ND       | 0   | 2   | 1      | cPR             | grade 2             | TC | 6             | DOD     | 10            |
| 21       | 73/M    | P         | G2>3  | ≥pT1a | ND       | 0   | 2   | 2      | cPR             | —                   | TUR| 18            | NED     | 32            |
| 22       | 42/M    | P         | G1>2  | ≥pT1a | ND       | 0   | 0   | 2      | cPR             | —                   | TUR| —             | NED     | 40            |
| 23       | 61/M    | N         | G2    | ≥pT1a | ND       | 0   | 3   | 2      | cPR             | grade 2             | TC | —             | NED     | 22            |

IAC, intraarterial chemotherapy; No. IAC, number of IAC given; Tx, treatment after IAC; Time to PD, time to disease progression from initiation of IAC; N, non-papillary tumor; P, papillary tumor; wt, wild type; mt, mutant type; ND, not determined; TC, total cystectomy; PC, partial cystectomy; TUR, transurethral resection; NED, no evidence of disease; DOD, death of disease; DOO, death of other causes; AWD, alive with metastatic disease; AWR, alive with local recurrence; m, months.

a) Case 21 underwent total cystectomy for recurrent T2 disease at 26 months after IAC.

Table I. Clinicopathological Characteristics, p53 Gene Status, p53 and p21 Immunoreactivity, Response to IAC and Prognosis
Subsequent treatments after IAC or PR) and poor responders (NC). Patients were divided into 2 groups; good responders (CR or PR) and poor responders (NC).

**Subsequent treatments after IAC** In principle, good responders to the first cycle of IAC underwent the second cycle and poor responders to the first cycle of IAC underwent subsequent surgical treatments. Subsequent surgical modalities including total cystectomy, partial cystectomy and TUR were selected considering patients’ general status and request.

**p53 gene status** DNA extracted from biopsied fresh tumor tissue was amplified from exons 5 to 8 of the p53 gene using polymerase chain reaction (PCR). PCR conditions consisted of 40 cycles of 95°C for 1.5 min (denaturation), 48°C for 1.5 min (extension) and 70°C for 2 min (annealing). The PCR products underwent single strand conformation polymorphism (SSCP) analysis. The DNAs in which mutations were detected by SSCP analysis were then sequenced.

**Immunohistochemical staining** Immunohistochemical staining was performed to study p53 overexpression and p21 expression in tumor tissues. Five-micrometer formalin-fixed, paraffin-embedded tissue sections were mounted on sialinized slides. The sections were deparaffinized in xylene and rehydrated in a graded alcohol series. Following treatment with 3% hydrogen peroxide in methanol to exhaust endogenous peroxidase activity, the sections for p21 staining were pretreated in a microwave oven three times for 5 min at 500 W in 10 mM citrate buffer. After blocking of nonspecific binding with 10% rabbit serum, sections were incubated with 5 μg/ml of mouse monoclonal antibody against p53 protein (PAb1801, Oncogene Science, Cambridge, MA) or p21 protein (EA10, Oncogene Research Products, Cambridge, MA) at 4°C overnight followed by two washes with Tris-buffered saline (TBS). The sections were incubated with biotinylated rabbit anti-mouse IgG at room temperature for 50 min followed by two washes with TBS, then reacted with 3,3’-diaminobenzidine tetrahydrochloride (DAB)/hydrogen peroxide solution for 30 min at room temperature. Finally, the sections were washed in water, counterstained with hematoxylin for 1 min, dehydrated and mounted.

Slides were independently reviewed by two of the authors (K. F. and A. K.) without knowledge of clinical information. Staining intensity for p53 and p21 was graded semiquantiatively into four categories by evaluating the percentage of nuclear staining of tumor cells. Categories of 0, 1+, 2+ and 3+ corresponded to negative staining (no nuclear reactivity), minor focally positive staining (1–9% of cells), heterogeneously positive staining (10–49% of cells) and homogeneously positive staining (50–100% of cells), respectively. Only samples demonstrating at least 10% nuclear reactivity (2+) were considered to be positive. We based this criterion on the report by Esrig et al. in which mutations in the p53 gene strongly correlated with the accumulation of p53 protein in 10% or more of the tumor-cell nuclei when the anti-p53 monoclonal antibody PAb1801 was used.

Known tumor sections of a TCC case with p53 mutations and normal bladder mucosa without p53 mutation were used as positive and negative controls, respectively, and normal colonic mucosa was used as a p21 positive control (positive nuclei in superficial epithelium). Normal bladder epithelia showed negative staining (0) for p21. Representative samples of p53 and p21 immunostaining are shown in Fig. 1.

**Statistics** Fisher’s exact test was used to assess the association between patients’ characteristics and responses to IAC. Probabilities of survival from the first cycle of IAC were estimated using the Kaplan-Meier method, and univariate tests of significance were performed using the log-rank test. Statistical analyses were performed with the statistical analysis systems package (StatView J-4.5, Abacus Concept, Inc., Berkley, CA). Differences were considered significant when the P value was less than 0.05.

**RESULTS**

**Results of mutation analysis and immunohistochemistry, and response to IAC** Of 19 patients, seven (37%) had mt p53 gene (Table I). Of 7 cases with mt p53 gene, 5 cases had missense mutations and the remaining 2 cases had a point mutation in the 3’ splice site of exon 7 and a 17-base pair deletion in exon 7. Case 16 showed both missense mutations of exon 7 and a 1-base pair deletion in the 3’ splice site of exon 8 (Table II).

Six (26%) of the 23 patients showed positive staining for p53. The mt p53 genes were detected in 3 of 6 cases with positive p53, and in 4 of 13 cases with negative p53 (Table I). There was no significant association between p53 gene status and p53 immunoreactivity (P = 0.61).

p21 expression was detected in 16 patients (70%) (Table I). The p21 immunoreactivity had no association with histological grade, p53 gene status or p53 immunoreactivity.

Thirteen patients received one cycle of IAC while 10 patients received 2 cycles. The overall objective response rate (incidence of good responders) and CR rate were 70% (16 of 23) and 17% (4 of 23), respectively. The overall response rate, incidence of grade 3 effect, CR rate, and incidence of grade 0 effect had no significant association with histological structure, grade or the number of IAC given.

**Response to IAC according to p53 gene status or p53 or p21 immunoreactivity** Patients with the wt p53 gene and negative staining for p53 tended to show a better...
response to IAC compared to patients with the mt p53 gene and positive staining for p53 (Table III). None of the 9 patients with p53 alterations (mt p53 gene and/or positive p53) achieved CR (Table III), and all of the 4 patients showing grade 0 effect had p53 alterations (Table I).

The patients with negative p53 showed a significantly higher objective response rate and lower incidence of grade 0 effect than patients with positive p53 (82% vs. 33%; P=0.045 and 10% vs. 75%; P=0.041, respectively). However, p53 gene status had no significant association with IAC response (Table III).

There was no significant association between p21 immunoreactivity and IAC response; the objective response rate was 81% in patients with positive p21 and 43% in those with negative p21 (P=0.14). Patients with positive p21 showed a CR rate of 13% and an incidence of grade 0 effect of 33% while those with negative p21 showed a CR rate of 29% and an incidence of grade 0 effect of 20% (P=0.56 and >0.99, respectively) (Table III).

| Case no. | PCR-SSCP | Codon | Nucleotide | Amino acid |
|----------|-----------|-------|------------|------------|
| 13 | exon 5 | 175 | CGC → CAG | Arg → His |
| 14 | exon 5 | 132 | AAG → GAG | Lys → Glu |
| 15 | exon 6 | 193 | CAT → CGT | His → Arg |
| 16 | exon 7 | 243 | ATG → ATT | Met → Ile |
| 17 | exon 7 | 244 | GGC → TGC | Gly → Cys |
| 18 | exon 7 | 248 | CGG → CAG | Arg → Gln |
| 19 | exon 7 | 250–255 | 17 bp deletion | → |

**Response to IAC according to p53/p21 immunoreactivity** Based on both p53 and p21 immunohistochemical findings, 23 patients were divided into 4 groups; negative p53/positive p21 (12 patients), negative p53/negative p21 (disease progression or death).
(5 patients), positive p53/positive p21 (4 patients) and positive p53/negative p21 (2 patients) (Table IV). The negative p53/positive p21 group showed an objective response rate of 92%, which was significantly higher than the positive p53 and/or negative p21 groups (45%; P=0.027). Both patients of the positive p53/negative p21 group showed NC while 24% of patients of the negative p53 and/or positive p21 groups showed NC (P=0.083). Nine patients in the negative p53/negative p21 and positive p53/positive p21 groups had no apparent trend in IAC response (Table IV).

Follow-up data Patients were stratified by p53 gene status, p53 immunoreactivity, p21 immunoreactivity, p53/p21 immunoreactivity, responses to IAC and post-IAC therapeutic modalities, and assessed for differences in cause-specific and progression-free survival. For patients whose bladders were preserved after IAC, disease progression was defined as the recurrence of muscle-invasive (≥T2) bladder cancer as well as the development of extravesical diseases. The mean follow-up period from the initial IAC therapy was 19 months (3–42 months). Within this period, disease progression was observed in 12 patients (6 of them belonged to the bladder preservation group) and 6 patients died of the disease. Three other patients died of other causes. Of 9 good responders whose bladders were preserved, 3 patients developed recurrent muscle-invasive disease and 2 other patients relapsed in distant sites. Estimated 1.5-year cause-specific and progression-free survival rates of patients stratified by each factor are shown in Table V. The negative p53 group showed a significantly longer cause-specific survival period (P=0.015) and a strong trend for a longer progression-free survival period (P=0.057). The good responders also showed a trend for longer cause-specific and progression-free survival periods (P=0.076 and 0.094, respectively). The other factors did not affect survival.

**DISCUSSION**

Following DNA damage, p53 protein levels rise dramatically in cells bearing the wt p53 gene. The p53 protein transcriptionally regulates expression of the downstream effector genes including p21/WAF1/CIP1 (p21), bax, bcl-2 and Fas, and eventually allows DNA repair or triggers cell death by apoptosis.6) Missense mutations and deletions in exons 5–8 of the p53 gene, which encode the DNA-binding domain of the p53 protein, usually abolish wt p53 function, prolong the half-life of the protein from minutes to hours and result in nuclear accumulation of the p53 protein allowing its detection by immunohistochemistry.6)

---

**Table III. IAC Response according to p53 Immunoreactivity, p53 Gene Status, and p21 Immunoreactivity**

| p53 Gene Status | Grade 3 effect | CR | CR+PR | Grade 0 effect |
|-----------------|----------------|-----|-------|----------------|
| Negative (%)    | Positive (%)   |     |       |                |
| Grade 3 effect  | 2/10 (20)      | 0/4 (0) | 4/17 (24) | 1/10 (10)  |
| Positive (%)    |               |       |       |                |
| wt (%)          | 2/7 (29)       | 0/5 (0) | 4/12 (33) | 1/7 (14)    |
| mt (%)          | 0/9 (0)        | 2/5 (40) | 0/7 (10) | 0/5 (0)     |
| Positive (%)    | 2/5 (40)       |       |       |                |

CR: grade 3 effect+cCR. PR: grade 2 effect+cPR.

**Table IV. IAC Response according to p53/p21 Immunoreactivity**

| p53/p21          | CR Grade 3 effect | PR Grade 2 effect | NC Grade 0 effect | Total CR+PR(%) |
|------------------|-------------------|-------------------|-------------------|---------------|
| Negative p53/positive p21 | 0 2 | 5 4 | 0 0 1 | 12 92 |
| Negative p53/negative p21 | 2 0 | 0 1 | 2 0 0 | 5 60 |
| Positive p53/positive p21 | 0 0 | 0 1 | 0 0 2 | 4 50 |
| Positive p53/negative p21 | 0 0 | 0 0 | 0 1 1 | 2 0 |

Good responders: negative p53/positive p21=92% (11/12), positive p53 and/or negative p21=45% (5/11). P=0.027.

420
Although abrogation of wt p53 function affects the normal cell response to DNA damage, the relationship between p53 status and chemosensitivity remains controversial.

The p21 gene is an important downstream target for the p53 protein to generate growth suppression, DNA repair and apoptosis.7–10 p21 gene alterations are rare in human cancers, indicating that the p21 gene is not associated with oncogenesis.20, 21 The p21 gene product, p21 protein, inhibits cell cycle progression and DNA replication through binding to cyclin-dependent kinases and PCNA.7–10 Overexpression of p21 alone results in not only growth suppression, but also G1-cell cycle arrest and apoptosis in vitro.7–10 Accordingly, p21 is considered to prevent progression of tumors. Actually, clinical studies have shown that p21 expression is a significant factor associated with good prognosis in some malignancies, including bladder cancer.22 Besides the functions of p21 as an apoptosis-inducer and a growth suppressor, p21 contributes to DNA repair in DNA-damaged cells.6 Therefore, it remains controversial whether p21 contributes to a favorable result of cytotoxic chemotherapy or not.

The relationship between chemosensitivity and wt p53 and p21 is currently considered from two mutually exclusive points of view: (1) cells bearing wt p53 and p21 are chemosensitive because after exposure to DNA-damaging drugs they undergo apoptosis through cell cycle arrest11–14 and (2) cells bearing wt p53 and p21 are chemoresistant because following DNA damage they are protected from cell death through cell cycle arrest and DNA repair.15, 16 Waldman et al. have supported the latter viewpoint; they have shown that following DNA damage, cells lacking wt p53 or p21 can undergo and often complete DNA synthesis in the absence of mitosis (uncoupling of synthesis phase and mitosis) due to loss of the G1-cell cycle checkpoint, acquire deformed, polyploid nuclei and subsequently die through apoptosis.16 In the clinical setting, Cote et al. have reported that following radical cystectomy, adjuvant chemotherapy including the DNA-damaging agents cisplatin and doxorubicin improves survival only in patients with p53-altered bladder cancer, suggesting that abrogation of wt p53 functions increases chemosensitivity.23

In the present study, patients with p53-negative tumors had a significantly higher objective response rate and lower incidence of grade 0 effect than patients with p53-positive tumors. Moreover, grade 3 effect and cCR were observed only in patients with p53-negative tumors. Our results are consistent with the report of Kakehi et al. that p53-negative urothelial carcinomas have responded better to cisplatin-based neoadjuvant chemotherapy than p53-positive carcinomas.24 These findings suggest that wt p53 protein increases the chemosensitivity of urothelial cancer in the primary sites. As for metastatic urothelial carcinomas, 3 recent studies failed to demonstrate a correlation between the p53 staining status of primary tumors and the effect of chemotherapy on metastatic disease.24–26 The difference in chemosensitivity between primary and metastatic tumors might be based on cumulative molecular changes of apoptosis-related genes having more critical roles than p53 gene in metastatic tumors. However, these events in tumors could not explain the strikingly contrasting results to ours in the study of adjuvant chemotherapy targeting micrometastatic disease.23 A further large-scale study is needed to elucidate whether the relationship of p53 staining status of tumors at the primary sites with chemosensitivity is actually different between the primary, micrometastatic and gross metastatic tumors, or not.

In the study of Esrig et al. on bladder cancer, 84% of tumors with evidence of mutation in the p53 gene by molecular analysis showed p53 nuclear accumulation in
ogy as Esrig.

Improved survival if tumors expressed p21 or did not express p53. A high incidence of discordant cases in our study may be mainly due to sampling bias; we used only a small amount of fresh tumor tissue for SSCP analysis while entire biopsy specimens were screened to assess the p53 immunoreactivity. Considering tumor heterogeneity, we believe that p53 staining results reflect tumor characteristics associated with p53 functions rather than SSCP results in the present study.

Concerning the relationship between p21 staining status and responsiveness to chemotherapy, there have been a few clinical studies. In a study of pancreatic adenocarcinoma, adjuvant chemotherapy or radiation significantly improved survival if tumors expressed p21 or did not express p53. In our study, p21 immunoreactivity alone did not significantly affect response to IAC. Therefore, p21 staining status seemed less predictive of chemotherapeutic response than p53 status. However, when patients were stratified by the combination of p53 and p21 staining status, negative p53/positive p21 and positive p53/negative p21 were better predictors of good responders (92%; 11/12) and poor responders (100%; 2/2) than negative p53 alone (82%; 14/17) and positive p53 alone (67%; 4/6), respectively. This suggests that p21 enhances the chemosensitivity of the primary bladder cancer, regardless of p53 status.

The relationship between p53 status and prognosis of patients with invasive bladder cancer has been well established; patients with p53-altered tumors have a poor prognosis. Survival data in the present study are consistent with the study of Sarkis et al., in which patients with p53-negative bladder cancer have a significant survival advantage compared to those with p53-positive bladder cancer following neoadjuvant systemic chemotherapy composed of methotrexate, vinblastin, adriamycin and cisplatin. These results may reflect the aggressiveness and chemoresistance of p53-positive tumors. Concerning p21 status, Stein et al. reported that positive p21 was a significant and independent predictor of favorable prognosis in patients who underwent cystectomy for bladder cancer. However, in the present study, we found no difference in survival according to p21 staining status. Because of the small sample size and short follow-up duration of the present study, we cannot reach a clear conclusion about the relationship between p21 status and survival in patients with bladder cancer. A large-sized study is required to elucidate the association of p21 status with the prognosis of patients with bladder cancer treated with neoadjuvant chemotherapy.

In conclusion, negative p53/positive p21 immunostaining is a possible predictor of favorable response to IAC in patients with locally advanced transitional cell carcinoma (TCC) of the bladder. Accordingly, wt p53 and p21 protein are likely to increase sensitivity to DNA-damaging drugs by favoring apoptosis, rather than to decrease chemosensitivity by enhancing DNA repair in TCC.

References

1) McCaffrey, J. A., Bajorin, D. F., Scher, H. I. and Bosl, G. J. Combined-modality therapy for bladder cancer. Oncology (Huntingt.), 11, 18–26 (1997).
2) Freiha, F., Reese, J. and Torti, F. M. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol., 155, 495–500 (1996).
3) Splinter, T. A. W., Scher, H. I., Denis, L., Bukowski, R., Simon, S., Klimberg, I., Soloway, M., Vogelzang, N. J., Tinteren, H., Herr, H. and EORTC-GU Group. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J. Urol., 147, 606–609 (1992).
4) Sternberg, C. N., Arena, M. G., Calabresi, F., Carli, P. D., Platania, A., Zeuli, M., Giannarelli, D., Cancrini, A. and Pansadoro, V. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer, 72, 1975–1982 (1993).
5) Arima, K., Tochigi, H., Sugimura, Y. and Kawamura, J. Balloon-occluded arterial infusion as a useful neoadjuvant chemotherapy for bladder cancer. Br. J. Urol., 80, 417–420 (1997).
6) Harris, C. C. Structure and function of p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88, 1442–1455 (1996).
7) El-Deiry, W., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817–825 (1993).
8) Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805–816 (1993).
9) Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701–704 (1993).
10) El-Deiry, W., Harper, J. W., O’Connor, P. M., Velculescu, V. E., Caman, C. E., Jackman, J., Pietenpol, J. A., Burrel, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E.,
Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169–1174 (1994).

11) Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, E. and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391–3395 (1994).

12) Kawasaki, T., Tomita, Y., Bilim, V., Takeda, M., Takahashi, K. and Kumanishi, T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int. J. Cancer, 68, 501–505 (1996).

13) Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B. and Barnett, G. H. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene, 13, 1279–1285 (1996).

14) Blagosklonny, M. V. and El-Deiry, W. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int. J. Cancer, 75, 933–940 (1998).

15) Hawkins, D., Demers, W. and Galloway, D. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892–898 (1996).

16) Waldman, T., Lengauer, C., Kinzler, K. W. and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381, 713–716 (1996).

17) International Union Against Cancer. “TNM Atlas,” 4th Ed. (1997). Springer, Tokyo.

18) Japanese Urological Association and the Japanese Society of Pathology. “General Rule for Clinical and Pathological Studies on Bladder Cancer,” 2nd Ed. (1993). Kanehara Co., Tokyo.

19) Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S., Skinner, D. G., Jones, P. A. and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143, 1389–1397 (1993).

20) Watanabe, H., Fukuchi, K., Takagi, Y., Tomoyasu, S., Tsuruoka, N. and Gomi, K. Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim. Biophys. Acta, 1263, 275–280 (1995).

21) Lacombe, L., Orlow, I., Silver, D., Gerald, W. L., Fair, W. R., Reuter, V. E. and Cordon-Cardo, C. Analysis of p21 WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8, 409–414 (1996).

22) Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G. and Cote, R. J. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90, 1072–1079 (1998).

23) Cote, R. J., Esrig, D., Groshen, S., Jones, P. A. and Skinner, D. G. p53 and treatment of bladder cancer. Nature, 385, 123–124 (1997).

24) Kakehi, Y., Özdemir, E., Habuchi, T., Yamabe, H., Hashimura, T., Katsura, Y. and Yoshida, O. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn. J. Cancer Res., 89, 214–220 (1998).

25) Sengelov, L., Horn, T. and Steven, K. p53 nuclear reactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J. Cancer Res. Clin. Oncol., 123, 565–570 (1997).

26) Siu, L. L., Banerjee, D., Khurana, R. J., Pan, X., Pfueger, R., Tannock, I. F. and Moore, M. J. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Cancer Res., 4, 559–565 (1998).

27) Dergham, S. T., Dugan, M. C., Joshi, U. S., Chen, Y. C., Du, W., Smith, D. W., Arlauskas, P., Crissman, J. D., Vaitkevicius, V. K. and Sarkar, F. H. The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. Cancer, 80, 372–381 (1997).

28) Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331, 1259–1264 (1994).

29) Uchida, T., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kameya, T. and Koshiha, K. p53 mutations and prognosis in bladder tumors. J. Urol., 153, 1097–1104 (1995).

30) Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C. and Scher, H. I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13, 1384–1390 (1995).